SV2017005585A - Peptidos lipidados resistentes a proteasas - Google Patents

Peptidos lipidados resistentes a proteasas

Info

Publication number
SV2017005585A
SV2017005585A SV2017005585A SV2017005585A SV2017005585A SV 2017005585 A SV2017005585 A SV 2017005585A SV 2017005585 A SV2017005585 A SV 2017005585A SV 2017005585 A SV2017005585 A SV 2017005585A SV 2017005585 A SV2017005585 A SV 2017005585A
Authority
SV
El Salvador
Prior art keywords
peptides
proteasas
resistant
lipided
amino acids
Prior art date
Application number
SV2017005585A
Other languages
English (en)
Inventor
Jefferson D Revell
Maria A Bednarek
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SV2017005585A publication Critical patent/SV2017005585A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA PÉPTIDOS RESISTENTES A PROTEASAS, MÉTODOS DE PREPARACIÓN DE TALES PÉPTIDOS, ASÍ COMO COMPOSICIONES QUE COMPRENDEN PÉPTIDOS RESISTENTES A PROTEASAS Y MÉTODOS DE TRATAMIENTO QUE UTILIZAN TALES PÉPTIDOS. UNA COMBINACIÓN DE LIPIDACIÓN DE DETERMINADOS RESIDUOS DE AMINOÁCIDOS Y SUSTITUCIÓN DE AMINOÁCIDOS FUNCIONALIZADOS CON ALFA-METILO EN LUGAR DE AMINOÁCIDOS NATURALES PARA PRODUCIR PÉPTIDOS RESISTENTES A PROTEASAS
SV2017005585A 2015-06-10 2017-12-08 Peptidos lipidados resistentes a proteasas SV2017005585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US201662343390P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
SV2017005585A true SV2017005585A (es) 2018-05-22

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005585A SV2017005585A (es) 2015-06-10 2017-12-08 Peptidos lipidados resistentes a proteasas

Country Status (25)

Country Link
US (3) US10414811B2 (es)
EP (2) EP3307769B1 (es)
JP (1) JP6811190B2 (es)
KR (1) KR20180016441A (es)
CN (1) CN108271373B (es)
AU (2) AU2016277449B2 (es)
CA (1) CA2988841C (es)
CL (1) CL2017003144A1 (es)
CO (1) CO2017012675A2 (es)
CR (1) CR20170559A (es)
DO (1) DOP2017000287A (es)
EA (1) EA036415B1 (es)
ES (1) ES2849950T3 (es)
IL (1) IL255978B (es)
MX (1) MX2017015482A (es)
MY (1) MY185816A (es)
NI (1) NI201700156A (es)
NZ (1) NZ738909A (es)
PE (1) PE20180659A1 (es)
PH (1) PH12017502259A1 (es)
SG (1) SG10201911837SA (es)
SV (1) SV2017005585A (es)
TN (1) TN2017000519A1 (es)
TW (1) TWI726889B (es)
WO (1) WO2016198544A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190017017A (ko) * 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
WO2019087083A2 (en) * 2017-10-31 2019-05-09 Medimmune, Llc Oral delivery of glp-1 peptide analogs
EP4364751A3 (en) 2018-04-05 2024-06-26 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
EP2497781A1 (en) * 2005-09-08 2012-09-12 Trustees Of Tufts College Stabilized GLP-1 analogs
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
MX2010006287A (es) 2007-12-11 2010-10-26 Cadila Healthcare Ltd Peptidomimeticos con actividades antagonistas de glucagon y agonistas del peptido 1 similar al glucagon.
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
EP2491054A2 (en) 2009-10-22 2012-08-29 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EP3459598A1 (en) * 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
EP3238734A1 (en) * 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
KR20160098406A (ko) 2013-12-13 2016-08-18 메디뮨 리미티드 프로테아제 내성 펩티드

Also Published As

Publication number Publication date
EP3865504A1 (en) 2021-08-18
SG10201911837SA (en) 2020-01-30
AU2016277449B2 (en) 2019-06-20
NI201700156A (es) 2018-10-18
US20200079833A1 (en) 2020-03-12
IL255978B (en) 2021-04-29
US20210221866A1 (en) 2021-07-22
EA201792640A1 (ru) 2018-06-29
IL255978A (en) 2018-01-31
KR20180016441A (ko) 2018-02-14
EP3307769A1 (en) 2018-04-18
AU2019229424A1 (en) 2019-10-03
EA036415B1 (ru) 2020-11-09
US20180162920A1 (en) 2018-06-14
PE20180659A1 (es) 2018-04-17
JP6811190B2 (ja) 2021-01-13
CN108271373B (zh) 2021-12-28
TW201710287A (zh) 2017-03-16
DOP2017000287A (es) 2018-04-15
EP3307769B1 (en) 2020-12-02
TWI726889B (zh) 2021-05-11
CN108271373A (zh) 2018-07-10
TN2017000519A1 (en) 2019-04-12
PH12017502259A1 (en) 2018-06-25
WO2016198544A1 (en) 2016-12-15
CL2017003144A1 (es) 2018-04-13
MY185816A (en) 2021-06-10
JP2018518485A (ja) 2018-07-12
CR20170559A (es) 2018-05-11
ES2849950T3 (es) 2021-08-24
CA2988841A1 (en) 2016-12-15
AU2016277449A1 (en) 2018-02-01
CA2988841C (en) 2023-06-06
US10414811B2 (en) 2019-09-17
NZ738909A (en) 2019-08-30
MX2017015482A (es) 2018-02-09
CO2017012675A2 (es) 2018-02-28

Similar Documents

Publication Publication Date Title
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
MX2023008686A (es) Polinucleotidos moduladores.
BR112017010173A2 (pt) composição para tratamento de tecido
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
BR112017010177A2 (pt) composição para tratamento de tecido
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX2021010060A (es) Produccion de virus en huevos aviares.
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
MX2017000862A (es) Formulacion de factor viii.
BR112016019389A8 (pt) Vacina, e, peptídeo
IN2014CH00840A (es)
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
EA201990181A1 (ru) Получение активированных клостридиальных нейротоксинов
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations